> Ask the expert: Triple-negative breast cancer with Foluso Olabisi Ademuyiwa (Bisi), MD, MPH, MSCI

Ask the expert: Triple-negative breast cancer

with Foluso Olabisi Ademuyiwa (Bisi), MD, MPH, MSCI

Date and Time

Wed, Sep 23, 2020 7:00 pm to 8:00 pm ET

Location

Virtual

Watch webinar recording

Date and Time

Wed, Sep 23, 2020 7:00 pm to 8:00 pm ET

Location

Virtual

Watch webinar recording
general_content

Event details

About 15 to 20 percent of breast cancers are triple-negative, but it can still be a misunderstood breast cancer subtype. Listen to this webinar, Ask the Expert: Triple-Negative Breast Cancer to get answers to your questions on this subtype, who it affects, treatment options, and side effects for early stage and metastatic breast cancer.

This webinar features speaker Foluso Olabisi Ademuyiwa (Bisi), MD, MPH, MSCI. Dr. Ademuyiwa is a breast medical oncologist and associate professor at Washington University in St. Louis.

Understanding your subtype and its treatment options will help you make the best decisions for you. Learn more about TNBC and three common myths.

video
audio_embed
speakers_feature

About our expert

Foluso Olabisi Ademuyiwa headshot

Foluso Olabisi Ademuyiwa (Bisi), MD, MPH, MSCI

Foluso Olabisi Ademuyiwa (Bisi), MD, MPH, MSCI, is an expert in the management of all types of breast cancer. She provides patient-centered care as part of a multidisciplinary breast cancer team. Dr. Ademuyiwa is actively involved in research on triple-negative breast cancer and racial disparities in breast cancer research and serves as principal investigator on multiple clinical trials.

Learn more
3 Tier Sponsors

Event sponsor

upcoming_events

Upcoming Events

Updates from the 2024 San Antonio Breast Cancer Symposium

Tue, Dec 17, 2024

Learn More

Thriving Together: 2025 Conference on Metastatic Breast Cancer

Fri, Mar 07, 2025

Learn More
View All Events View Past Events
related_resources_article_carousel

Related articles

Immunohistochemistry (IHC) tests

11/15/24 | BY: Regina Hampton

Some of the most important breast cancer treatment decisions are based on immunohistochemistry (IHC) tests; hormone receptor status, HER2 status, and in some cases, PD-L1 status.

Read More
 | 7 Min. Read

Triple-negative

12/19/23 | BY: Reshma L. Mahtani

Triple-negative breast cancers (TNBC) test negative for hormone and HER2 receptors. About 10% to 15% of breast cancers are triple-negative.

Read More
 | 13 Min. Read |

Triple-negative metastatic breast cancer

05/01/23 | BY: Rita Nanda

Metastatic triple-negative breast cancer is a rare form of aggressive breast cancer. Learn more its symptoms, diagnosis, and treatment options.

Read More
 | 11 Min. Read |

Sacituzumab govitecan

02/03/23 | BY: Stephanie Graff

Sacituzumab govitecan (Trodelvy) is an antibody-drug conjugate, a treatment that pairs a chemotherapy medicine with a targeted therapy. It is approved to treat people diagnosed with several types of metastatic breast cancer.

Read More
 | 5 Min. Read |

Targeted therapy for triple-negative breast cancer

01/01/23 | BY: Zanetta Lamar

Learn more about the different classes of targeted therapies for triple-negative breast cancer, the tumor biomarkers that tell us who may benefit from them, and how they work.

Read More
 | 4 Min. Read |

Follow-up care for TNBC

04/18/18 | BY: Lisa Carey

Learn what follow-up care may be needed and what it entails following a treatment for triple-negative breast cancer.

Read More
 | 4 Min. Read |

Dealing with negative comments

04/18/18 | BY: Lisa Carey

Get tips on how to manage people who have opinions about your breast cancer treatment.

Read More
 | 6 Min. Read |

Risks and fear of recurrence

04/18/18 | BY: Lisa Carey

Find out about activities and emotional support to help quell anxiety and worry after treatment for triple-negative breast cancer. 

Read More
 | 3 Min. Read
stay_connected

Stay connected

Sign up to receive emotional support, medical insight, personal stories, and more, delivered to your inbox weekly.